Setmelanotide Cuts BMI by 18.8% in Phase 3, FDA Decision March 2026
In 142 acquired hypothalamic obesity patients, Phase 3 TRANSCEND data showed an 18.8% placebo-adjusted BMI reduction and a 16.4% mean BMI drop versus +2.4% on placebo at 52 weeks (p<0.0001). PDUFA date is March 20, 2026; EMA CHMP opinion due in Q2 with possible EU authorization in H2 2026.
1. TRANSCEND Trial Efficacy Data
Phase 3 TRANSCEND trial enrolled 142 patients with acquired hypothalamic obesity, including 12 Japanese cohort and 10 supplemental patients, achieving a placebo-adjusted BMI reduction of 18.8% at 52 weeks. Active patients saw a mean 16.4% BMI decline from baseline versus a 2.4% increase on placebo (p<0.0001), and hunger scores fell by 2.5 points weekly compared to 1.3 points for placebo (p=0.0015).
2. Regulatory Timeline
Rhythm expects a PDUFA decision for the setmelanotide sNDA on March 20, 2026, following the final data package submission on March 2. The EMA’s CHMP opinion is scheduled for Q2 2026 with potential EU marketing authorization in the second half of 2026, and a PMDA submission in Japan will follow to pursue local approval.
3. Commercial and Patient Impact
With an estimated 10,000 U.S. patients and similar numbers in Europe, plus 5,000-8,000 potential patients in Japan, setmelanotide aims to become the first approved therapy for acquired hypothalamic obesity. Rhythm’s broad commercialization preparations and ongoing dialogue with regulators position the company for rapid market entry upon approvals.